Moreover, gefitinib-mediated inhibition of EGFR destabilized PD-L1 surface expression in a GSK3β dependent fashion and enhanced tumor specific T cell immunity measured by CD8+ T cell IFNγ and granzyme B production. This evidence concerns the gene IFNG and neoplasm.